Search Results
Apr 22, 2026, 11:13 ET Model Perawatan Terpadu NOVI Health Hapus Kesenjangan antara Hasil Uji Klinis dan Penerapan Obat GLP-1 di Dunia Nyata
Studi awal menunjukkan, pendekatan terpadu antara obat GLP-1 dan pendampingan digital mampu menghasilkan penurunan berat badan sekitar 14,7% dalam 18 bulan pada populasi Asia multietnis (n=708). Hasil tersebut mendekati temuan uji klinis, dan kontribusi pendampingan digital terbukti signifikan.SINGAPURA, 22
More news about: NOVI Health
Apr 22, 2026, 08:54 ET Clean Eatz Kitchen Publishes Senior Meal Delivery Comparison Ahead of Older Americans Month, Identifies Subscription Model as Key Barrier for Family Caregivers
Kitchen offers chef-prepared, dietitian-designed frozen meals shipped nationwide. Meal plans include Weight Loss, High Protein, Gluten-Free, GLP-1, and Build Your Own, starting at $8.49 per meal. No subscriptions required. Always-free shipping on all meal plan orders. More at
More news about: CE Kitchen Inc
Apr 22, 2026, 08:00 ET RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
Phase 2 study in prostate cancer in combination with darolutamide; (ii) RHB-102, with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.
Apr 22, 2026, 05:40 ET Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
company built around Hengrui Pharma's GLP-1-based assets. This milestone reflects continued progress in executing the Company's NewCo strategy, with Hengrui and Kailera working together to advance the global development of the GLP-1 portfolio.Looking ahead, Hengrui Pharma
More news about: Hengrui Pharma
Apr 21, 2026, 10:00 ET Ambrosia Biosciences Announces Late-Breaking Poster Presentation at the American Diabetes Association's (ADA) 86th Scientific Session
Poster presentation will feature the preclinical profile of Ambrosia's novel oral small molecule GLP-1 receptor agonist development candidate, AMB-702BOULDER, Colo., April 21, 2026
More news about: Ambrosia Biosciences
Apr 21, 2026, 09:33 ET New Pivot App Launches with Innovative GLP-1 Tracking to Support Personalized Weight Management Journeys
/PRNewswire/ -- Pivot, a new GLP-1 tracking app designed to help individuals optimize and personalize their weight management experience, today announced it is now available on IOS and Android platforms. Built for patients using GLP-1 medications, Pivot bridges the gap
More news about: Pivot
Apr 21, 2026, 09:05 ET Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery
industry's attention at the 11th and 12th Aging Research and Drug Discovery (ARDD). His keynote, "GLP-1s: The World's First Longevity Drug?", crystallized the emerging role of metabolic regulators
More news about: Insilico Medicine
Apr 21, 2026, 09:01 ET Rich, Creamy and Better Than Ever: A New Generation of I Can't Believe It's Not Butter!® Extra Creamy Products with Fresh Cream Deliver Rich Texture with Essential Nutrients
Omega-3 ALA per serving.The I Can't Believe It's Not Butter! products that carry the NutriRich designation can help support a GLP-1 diet by providing certain nutrients that may be missing in a diet due to reduced food intake.I Can't Believe It's Not Butter! Extra
More news about: Flora Food Group
Apr 21, 2026, 07:00 ET Greenvit Debuts ARONVIT® for Gut Health and Microbiota at Vitafoods Europe
1Blood sugar support via GLP-1 and enzymatic modulationA healthy microbiome replete with SCFAse naturally stimulates the L-cells in the gut lining. These L-cells are responsible for secreting intrinsic GLP-1 (glucagon-like peptide-1,
More news about: Greenvit
Apr 20, 2026, 04:17 ET Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline
FP012, a global first-in-class TL1A x IL10MM fusion protein for inflammatory bowel disease and other inflammatory indications, with IND-enabling CMC/GLP toxicology planned in 2026.Complementing this platform is Fapon Biopharma's proprietary VHH human-monkey cross-binding T-cell engager platform,
More news about: Fapon Biopharma
Apr 19, 2026, 20:15 ET CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
half-life of approximately 2 days. In human FcRn transgenic mice, the half-life was approximately 2.5–8 days.Controllable toxicity: GLP toxicology studies determined the highest non-severe toxic dose (HNSTD) to be 30 mg/kg.Safety window: No lethal toxicity was observed.
More news about: CStone Pharmaceuticals
Apr 19, 2026, 11:30 ET PureHealth Research GLP-1 Supplements Blend African Mango and Green Coffee Extract for Daily Satiety Support
Meet GLP-1 – Your Body's Built-In Appetite RegulatorGLP-1 is a hormone the body produces naturally after eating. It signals the brain that enough food has been consumed,
More news about: PureHealth Research LLC
Apr 17, 2026, 11:36 ET Food Starch Market to Reach USD 29.1 Billion by 2036 Amid Rising Demand for Clean-Label and Traceable Ingredients | Future Market Insights
complexityFaster product development cyclesStronger supplier partnershipsEmerging Demand from GLP-1 Nutrition TrendsThe rise of GLP-1-based dietary patterns is influencing starch demand in:Medical nutritionPortion-controlled
More news about: Future Market Insights
Apr 16, 2026, 08:35 ET Clean Eatz Kitchen Publishes High-Protein Meal Delivery Comparison as Summer Fitness Season Begins
of protein delivered — as a more useful measure than per-meal pricing alone when evaluating services for muscle building, weight loss, or GLP-1 medication support. A protein-per-dollar comparison of meal delivery services shows significant differences across major providers. Trifecta's
More news about: CE Kitchen Inc
Apr 16, 2026, 08:24 ET Digital Medicine Society Launches Initiative to Build Trusted Direct-to-Patient (DTP) Pathways for Pharma
rightDirect-to-patient (DTP) models are already a meaningful part of how patients access care, particularly in high-demand areas like GLP-1 therapies, where cash-pay pathways have expanded rapidly in response to access constraints, pricing complexity, and unmet demand.Recent federal
More news about: Digital Medicine Society (DiMe)
Apr 16, 2026, 06:45 ET ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
error.The overall safety and tolerability profile of Foundayo in ACHIEVE-4 was generally consistent with previous trials and with the GLP-1 class. The most common adverse events for patients taking Foundayo were nausea, vomiting, diarrhea, decreased appetite, and constipation. During
More news about: Eli Lilly and Company
Apr 15, 2026, 08:32 ET OmniActive's Study Shows Capsimax Supports Natural GLP-1 Activity and Metabolism
performance, resting energy expenditure (REE), and a GLP-1 outcome. Key results include:Approximately 13 percent increase in GLP-1 levels following seven days of supplementationSignificant increase in
More news about: OmniActive Health Technologies
Apr 15, 2026, 08:21 ET Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide
(orforglipron), Eli Lilly and Company's FDA-approved once-daily oral GLP-1 therapy for weight management. The addition gives Shed members a clinically proven, needle-free alternative to injectable GLP-1 treatments — one that requires no special meal timing and fits naturally into
More news about: Shed
Apr 15, 2026, 08:02 ET TOM BRADY LAUNCHES EXCLUSIVE GLP-1 OFFER FOR HEALTHCARE WORKERS
the premier employer platform for clinically supervised GLP-1 management. In a landscape marked by disconnected providers, cash-pay shortcuts, and inconsistent oversight, eMed offers a trusted, guided approach to GLP-1 care, one that prioritizes long-term health over short-term
More news about: eMed Population Health
Apr 15, 2026, 08:00 ET PrecisionLife and Ovation ink collaboration agreement to launch GLP-1 stratification LDT and consumer GLP-1 DNA test in H2 2026
outputs of PrecisionLife's analysis of Ovation's high quality GLP-1 receptor agonist dataset.
More news about: PrecisionLife Ltd
Apr 15, 2026, 08:00 ET ImmunoGenesis Announces Poster Presentation at AACR 2026 Annual Meeting
translational path, with pharmacologic activity confirmed across multiple species and pilot toxicology studies informing dose and delivery parameters for the GLP toxicology study and eventual clinical trial."IMGS-203 combines potent STING activation with a localized delivery approach designed to overcome
More news about: Immunogenesis Inc.
Apr 14, 2026, 11:15 ET Halo Effect of GLP-1s Signals New Consumer Lifestyle and Health and Wellness Trends
Acosta Group research reveals that GLP-1s are reshaping a growing segment of consumer behavior overall, expanding to include larger lifestyle, health and wellness, and personal care trends. The company is sharing the results of its new proprietary GLP-1 shopper study in advance of the National
More news about: Acosta Group
Apr 14, 2026, 09:00 ET Maven Clinic Expands Fertility and Family Building Program to Deliver Earlier Answers and More Efficient Fertility Spend
scale. Through its consumer platform, Maven provides direct access to virtual care across 30+ specialties, as well as dedicated hormone and GLP-1 care programs purpose-built for women.Founded in 2014 by CEO Kate Ryder, Maven Clinic has raised more than $425 million from leading healthcare
More news about: Maven Clinic
Apr 14, 2026, 08:36 ET PHE and Kindra Announce Strategic Commercial Partnership to Advance Sexual Health and Wellness
confidence, and quality of life through stages – from fertility to postpartum to perimenopause, and medication side effects from oral contraceptives to GLP1s.Established as PHE's "official partner for vaginal health and wellness," Kindra marks a significant expansion of PHE's portfolio of science-backed
More news about: PHE, Inc.
Apr 14, 2026, 07:00 ET Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
genetic level. The ability to shut down fat creation while activating fat metabolism differentiates GDNF from existing therapies, including GLP-1 agonists."SCIENTIFIC SUMMARY (HT-VA STUDY)The HT-VA study evaluated the effects of parenteral GDNF in a diet-induced obesity
More news about: Hoth Therapeutics, Inc.